A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT05923099. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-site, Parallel-group, Dose-finding Trial to Evaluate the Efficacy and Safety of Different Doses of Subcutaneously Administered LEO 138559 in Adult Subjects With Moderate-to-severe Atopic Dermatitis
Study identification
- NCT ID
- NCT05923099
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- LEO Pharma
- Industry
- Enrollment
- 262 participants
Conditions and interventions
Conditions
Interventions
- LEO 138559 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 19, 2023
- Primary completion
- Dec 10, 2024
- Completion
- Apr 8, 2025
- Last update posted
- Feb 11, 2026
2023 – 2025
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| LEO Investigational Site | Fountain Valley | California | 92708 | — |
| LEO Investigational Site | Los Angeles | California | 90045 | — |
| LEO Investigational Site | San Francisco | California | 94115 | — |
| LEO Investigational Site | Hialeah | Florida | 33012 | — |
| LEO investigational site | Indianapolis | Indiana | 46250 | — |
| LEO investigational Site | New Albany | Indiana | 47150 | — |
| LEO Investigational Site | Ann Arbor | Michigan | 48103 | — |
| LEO Investigational Site | New York | New York | 10029 | — |
| LEO Investigational Site | Raleigh | North Carolina | 27609 | — |
| LEO Investigational Site | Cincinnati | Ohio | 45219 | — |
| LEO Investigational Site | Mayfield Heights | Ohio | 44124 | — |
| LEO Investigational Site | North Charleston | South Carolina | 29420 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 61 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05923099, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 11, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05923099 live on ClinicalTrials.gov.